Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer... Show more
KURA is expected to report earnings to fall 76.89% to -15 cents per share on July 31
Q2'25
Est.
$-0.15
Q1'25
Missed
by $0.04
Q4'24
Beat
by $0.35
Q3'24
Est.
$-0.63
Q2'24
Beat
by $0.04
The last earnings report on May 01 showed earnings per share of -66 cents, missing the estimate of -62 cents. With 852.21K shares outstanding, the current market capitalization sits at 568.80M.